In vivo effect of two first-line ART regimens on inflammatory mediators in male HIV patients
Background Persistent immune activation and inflammation are lying behind HIV-infection even in the setting of ART mediated viral suppression. The purpose of this study is to define the in vivo effect of two first-line ART regimens on certain inflammatory mediators in male HIV patients. Methods Male, naive, HIV-infected volunteers were assigned either to tenofovir-DF/emtricitabine/efavirenz (Group_T) or abacavir/lamivudine/efavirenz (Group_A). Platelet Activating Factor (PAF) levels and metabolic enzymes together with HIV-implicated cytokines (IL-1beta, IL-6, IL-8, IL-10, IL-12p70, TNFa) and VEGF were determined for a 12-month period. Differences within each group were determined by non-parametric Friedman and Wilcoxon test, while the differences between the groups were checked by ANOVA repeated measures. Results Both ART regimens present pronounced effect on inflammatory mediators, resulting in decreased PAF levels and Lipoprotein-associated phospholipase A2 (Lp-PLA2) activity for tenofovir-containing regimen and same as baseline PAF levels with a peak though at the $ 3^{rd} $ month as well as elevated Lp-PLA2 activity for abacavir-containing regimen. Conclusions Studies regarding the effect of first-line ART regimens on inflammation may be beneficial in preventing chronic morbidities during HIV-treatment. From this point of view, the present study suggests an anti-inflammatory effect of tenofovir-containing ART, while the temporary increase of PAF levels in abacavir-containing ART may be the link between the reported cardiovascular risk and abacavir administration..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2014 |
|---|---|
| Erschienen: |
2014 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Lipids in health and disease - 13(2014), 1 vom: 29. Mai |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Papakonstantinou, Vasiliki D [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Abacavir |
|---|
| Anmerkungen: |
© Papakonstantinou et al.; licensee BioMed Central Ltd. 2014 |
|---|
| doi: |
10.1186/1476-511X-13-90 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR029239133 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR029239133 | ||
| 003 | DE-627 | ||
| 005 | 20230519171734.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/1476-511X-13-90 |2 doi | |
| 035 | |a (DE-627)SPR029239133 | ||
| 035 | |a (SPR)1476-511X-13-90-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Papakonstantinou, Vasiliki D |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a In vivo effect of two first-line ART regimens on inflammatory mediators in male HIV patients |
| 264 | 1 | |c 2014 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © Papakonstantinou et al.; licensee BioMed Central Ltd. 2014 | ||
| 520 | |a Background Persistent immune activation and inflammation are lying behind HIV-infection even in the setting of ART mediated viral suppression. The purpose of this study is to define the in vivo effect of two first-line ART regimens on certain inflammatory mediators in male HIV patients. Methods Male, naive, HIV-infected volunteers were assigned either to tenofovir-DF/emtricitabine/efavirenz (Group_T) or abacavir/lamivudine/efavirenz (Group_A). Platelet Activating Factor (PAF) levels and metabolic enzymes together with HIV-implicated cytokines (IL-1beta, IL-6, IL-8, IL-10, IL-12p70, TNFa) and VEGF were determined for a 12-month period. Differences within each group were determined by non-parametric Friedman and Wilcoxon test, while the differences between the groups were checked by ANOVA repeated measures. Results Both ART regimens present pronounced effect on inflammatory mediators, resulting in decreased PAF levels and Lipoprotein-associated phospholipase A2 (Lp-PLA2) activity for tenofovir-containing regimen and same as baseline PAF levels with a peak though at the $ 3^{rd} $ month as well as elevated Lp-PLA2 activity for abacavir-containing regimen. Conclusions Studies regarding the effect of first-line ART regimens on inflammation may be beneficial in preventing chronic morbidities during HIV-treatment. From this point of view, the present study suggests an anti-inflammatory effect of tenofovir-containing ART, while the temporary increase of PAF levels in abacavir-containing ART may be the link between the reported cardiovascular risk and abacavir administration. | ||
| 650 | 4 | |a Platelet activating factor |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Cytokines |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Inflammation |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Human immunodeficiency virus |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Cardiovascular disease |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Tenofovir-DF |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Abacavir |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Efavirenz |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Chini, Maria |4 aut | |
| 700 | 1 | |a Mangafas, Nikos |4 aut | |
| 700 | 1 | |a Stamatakis, George M |4 aut | |
| 700 | 1 | |a Tsogas, Nickolaos |4 aut | |
| 700 | 1 | |a Tsoupras, Alexandros B |4 aut | |
| 700 | 1 | |a Psarra, Katherina |4 aut | |
| 700 | 1 | |a Fragopoulou, Elizabeth |4 aut | |
| 700 | 1 | |a Antonopoulou, Smaragdi |4 aut | |
| 700 | 1 | |a Gargalianos, Panagiotis |4 aut | |
| 700 | 1 | |a Demopoulos, Constantinos A |4 aut | |
| 700 | 1 | |a Lazanas, Marios-C |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Lipids in health and disease |d London : Biomed Central, 2002 |g 13(2014), 1 vom: 29. Mai |w (DE-627)SPR029118360 |w (DE-600)2091381-3 |x 1476-511X |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2014 |g number:1 |g day:29 |g month:05 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/1476-511X-13-90 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2014 |e 1 |b 29 |c 05 | ||